Nora Maureen Rooney

Array ( [id] => 18724378 [patent_doc_number] => 20230338522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/028039 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561767 [patent_doc_number] => 20220125916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => PEANUT HYPOALLERGENIC FORMULATIONS FOR DETERMINING THE RISK OF ANAPHYLAXIS [patent_app_type] => utility [patent_app_number] => 17/510772 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17510772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480685 [patent_doc_number] => 20220088189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => IMMUNE MODULATION [patent_app_type] => utility [patent_app_number] => 17/501305 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369977 [patent_doc_number] => 20220025029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/500418 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578849 [patent_doc_number] => 20220135704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES [patent_app_type] => utility [patent_app_number] => 17/500794 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356827 [patent_doc_number] => 20220017623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/498512 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786129 [patent_doc_number] => 20230374142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => CLEC9A antibodies [patent_app_type] => utility [patent_app_number] => 18/029954 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 256 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601363 [patent_doc_number] => 20240392243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => DNA CONSTRUCTS FOR IMPROVED T CELL IMMUNOTHERAPY OF CANCER [patent_app_type] => utility [patent_app_number] => 18/246155 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808652 [patent_doc_number] => 20230382986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => FELINE ANTIBODY VARIANTS [patent_app_type] => utility [patent_app_number] => 18/246725 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20671954 [patent_doc_number] => 12612454 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-28 [patent_title] => Canine antibody variants [patent_app_type] => utility [patent_app_number] => 18/246716 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 15 [patent_no_of_words] => 16156 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923032 [patent_doc_number] => 20240026036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => COMPOUNDS AND METHODS FOR TREATING PAIN [patent_app_type] => utility [patent_app_number] => 18/246794 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775055 [patent_doc_number] => 20220241404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/478310 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769460 [patent_doc_number] => 20230364224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => Pharmaceutical Composition For Allergen Specific Immunotherapy [patent_app_type] => utility [patent_app_number] => 18/025985 [patent_app_country] => US [patent_app_date] => 2021-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861944 [patent_doc_number] => 20230416380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ANTIBODY BINDING HUMAN IL-5R alpha AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/025833 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627317 [patent_doc_number] => 20220162332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/471804 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18737945 [patent_doc_number] => 20230346847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => JUVENILE PROTECTIVE FACTORS TO ARREST AND REVERSE AGING IN THE ENTERIC NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 18/042912 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19164747 [patent_doc_number] => 11980629 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-14 [patent_title] => Conditioning regimens and methods for inducing mixed chimerism [patent_app_type] => utility [patent_app_number] => 17/399871 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 35 [patent_no_of_words] => 11983 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17399871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398204 [patent_doc_number] => 20220040294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => ADMINISTRATION OF VACCINES TO SITES OF TEMPORALLY INDUCED CELL-MEDIATED HYPERSENSITIVITY REACTIONS, TO FACILITATE THE DEVELOPMENT OF PROTECTIVE SENSITIZATION AGAINST INFECTIOUS DISEASES AND CANCERS [patent_app_type] => utility [patent_app_number] => 17/394506 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521130 [patent_doc_number] => 12122839 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => IFNGR binding synthetic cytokines and methods of use [patent_app_type] => utility [patent_app_number] => 18/006484 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 40582 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 622 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612394 [patent_doc_number] => 20230279126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/018444 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018444 [rel_patent_id] =>[rel_patent_doc_number] =>)